Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: A meta-analysis of randomized trials

Archives of Cardiovascular Diseases

Volumn 105, Issue 11, 2012, Pages 544-556

  Sethi, Ankur ^a   Bahekar, Amol ^a   Bhuriya, Rohit ^a   Bajaj, Anurag ^b   Singh, Param Puneet ^a   Arora, Rohit ^a   Khosla, Sandeep ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Wright Center of Graduate Medical Education   (United States)

Author keywords

Drug eluting stents; Percutaneous coronary intervention; Zotarolimus

Indexed keywords

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG ELUTING STENT; EMBASE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MORTALITY; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SIROLIMUS ELUTING STENT; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING STENT;

COATED MATERIALS, BIOCOMPATIBLE; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EQUIPMENT FAILURE; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHORYLCHOLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84869504555     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.01.014     Document Type: Article

References (28)

1. A.J. Kirtane, A. Gupta, and S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
2. A.A. Bavry, D.J. Kumbhani, and T.J. Helton Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061 (Pubitemid 44826931)
3. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
4. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern Circulation 115 2007 1440 1455 [discussion 55] (Pubitemid 46648381)
5. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510 (Pubitemid 46986103)
6. T.L. Pinto Slottow, and R. Waksman Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent Circulation 117 2008 1603 1608 (Pubitemid 351440648)
7. J.S. Kim, I.K. Jang, and T.H. Kim Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents Heart 95 2009 1907 1912
8. J. Fajadet, W. Wijns, and G.J. Laarman Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 114 2006 798 806 (Pubitemid 44268230)
9. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
10. B. Chevalier, C. Di Mario, and F.J. Neumann A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial JACC Cardiovasc Interv 1 2008 524 532
11. D.E. Kandzari, M.B. Leon, and J.J. Popma Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 2006 2440 2447 (Pubitemid 44881222)
12. C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 2009 1370 1376
13. M.B. Leon, L. Mauri, and J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
14. D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
15. K. Rasmussen, M. Maeng, and A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
16. E.L. Eisenstein, M.B. Leon, and D.E. Kandzari Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 2009 1199 1207
17. M.B. Leon, D.E. Kandzari, and E.L. Eisenstein Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 2009 1208 1218
18. S. Brugaletta, F. Burzotta, and M. Sabate Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective Expert Opin Pharmacother 10 2009 1047 1058
19. A. Schomig, A. Dibra, and S. Windecker A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease J Am Coll Cardiol 50 2007 1373 1380 (Pubitemid 47449734)
20. S. Windecker, A. Remondino, and F.R. Eberli Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization N Engl J Med 353 2005 653 662 (Pubitemid 41175673)
21. S.J. Pocock, A.J. Lansky, and R. Mehran Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials J Am Coll Cardiol 51 2008 23 32
22. A. Kaltoft, L.O. Jensen, and M. Maeng 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry) J Am Coll Cardiol 53 2009 658 664
23. N. Millauer, P. Juni, and A. Hofmann Sirolimus versus paclitaxel coronary stents in clinical practice Catheter Cardiovasc Interv 77 2011 5 12
24. E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 9851 2012 1396 1405
25. S. Garg, and P.W. Serruys Coronary stents: looking forward J Am Coll Cardiol 56 2010 S43 S78
26. A.C. Yeung, M.B. Leon, and A. Jain Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial J Am Coll Cardiol 57 2011 1778 1783
27. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, and G.A. van Es Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
28. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653 (Pubitemid 350182388)